A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial
Primary efficacy and safety results from the Phase 3 AMPOWER study evaluating Phexxi™ for the prevention of pregnancy were published in Contraception: X. The study found that Phexxi™, a novel vaginal pH regulator, demonstrated 86.3% contraceptive effectiveness, was safe and well tolerated, and was highly acceptable. These findings represent a major contribution to women’s health, with the forthcoming availability of a new, non-hormonal, woman-controlled method of contraception that expands women’s prevention options.
July 2020
Click for full info +Full Info:
Resource Type:
Citation:
The Phase 3 AMPOWER study found that Phexxi™, a novel vaginal pH regulator, demonstrated 86.3% contraceptive effectiveness, was safe and well tolerated, and was highly acceptable.
Authors:
Thomas, M.; Chappell, B.T.; Maximos, B.; Cullwell, K.; & Howard, B.
Health Risks(s):
- Unintended Pregnancy
Product type(s):
- Contraceptives
Topic(s):
- Development
- Trials
Region(s)
- Global